JAM
RIGL icon

Jupiter Asset Management’s Rigel Pharmaceuticals RIGL Stock Holding History

Jupiter Asset Management’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-1,162
Closed -$31K – 602
2021
Q4 		$31K Buy
+1,162
New +$35.1K ﹤0.01% 545

Other funds holding RIGL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Jupiter Asset Management's RIGL Position: Q1 2022 in Review

Jupiter Asset Management sold out of Rigel Pharmaceuticals (RIGL) in Q1 2022, closing a stake of 1,162 shares — an estimated $31K sold.

Jupiter Asset Management first reported a position in RIGL in Q4 2021 and held it in 1 quarter. The position peaked at $31K in Q4 2021. 163 funds tracked by Wall St. Rank hold RIGL as of Q1 2022.

  • Jupiter Asset Management reported no remaining Rigel Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • Jupiter Asset Management sold 1,162 Rigel Pharmaceuticals shares in Q1 2022, an estimated $31K.
  • Jupiter Asset Management first reported a position in Rigel Pharmaceuticals in Q4 2021 and held it in 1 quarter.
  • Jupiter Asset Management's Rigel Pharmaceuticals position peaked at $31K in Q4 2021.
  • 163 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q1 2022.

Based on Jupiter Asset Management's 13F filing for Q1 2022, filed 11 May 2022.